No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 5.5x · 10Y median 59.9x · 9th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T21:47:40.641Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Nyxoah S.A. (NYXH) stock was $1.43 as of Oct 6, 2026, 4:00 PM EDT, up 1.42% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -71.3% · 3-year avg -41.4%/yr · 5-year avg -45.8%/yr
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Medical - Specialties · Mont-Saint-Guibert, WA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · EUR
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.35
Revenue Est.
$11.25M
Last Quarter Results
EPS
$-0.67
vs Estimate
$-0.47
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NYXH | $143.10M | $1.43 | +1.42% | -71.34% | -45.84% | N/A | N/A |
| 2TARA | $143.60M | $2.56 | -2.85% | -46.82% | -16.45% | -38.82% | vs NYXH |
| 3NGEN | $143.84M | $1.75 | -3.31% | N/A | N/A | N/A | vs NYXH |
| 4FBIOP | $146.27M | $18.58 | +2.65% | +144.21% | +0.05% | N/A | vs NYXH |
| 5CDXS | $146.28M | $1.36 | -2.16% | -45.12% | -44.64% | -11.05% | vs NYXH |
| 6STRO | $139.84M | $14.45 | -4.49% | +66.22% | -39.51% | N/A | vs NYXH |
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$8.77M
vs Estimate
$8.64M
Consensus Rating
Based on 3 analysts
Average Price Target
$4.21
+194.7% upside
Low
$2.93
Current
$1.43
High
$5.81
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | EUR -0.36 | EUR -0.35 | EUR -0.34 | 3 |
| Quarter ending Dec 2026 | EUR -0.18 | EUR -0.18 | EUR -0.18 | 3 |
| Quarter ending Mar 2027 | EUR -0.26 | EUR -0.25 | EUR -0.24 | 1 |
| Quarter ending Jun 2027 | EUR -0.23 | EUR -0.22 | EUR -0.21 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | EUR -1.44 | EUR -1.27 | EUR -1.19 | 3 |
| FY 2027 | EUR -1.10 | EUR -0.79 | EUR -0.58 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | EUR 11.14M | EUR 11.25M | EUR 11.36M | 3 |
| Quarter ending Dec 2026 | EUR 15.07M | EUR 15.32M | EUR 15.56M | 3 |
| Quarter ending Mar 2027 | EUR 15.53M | EUR 15.92M | EUR 16.37M | 1 |
| Quarter ending Jun 2027 | EUR 18.26M | EUR 18.73M | EUR 19.25M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | EUR 41.94M | EUR 42.29M | EUR 42.65M | 5 |
| FY 2027 | EUR 76.33M | EUR 82.28M | EUR 88.24M | 5 |
